Epigenetics of colorectal cancer

Clinical Genetics

Volumn 81, Issue 4, 2012, Pages 312-318

  Migheli, F ^a   Migliore, L ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Colorectal cancer; Epigenetics; Folate; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; FOLIC ACID; HISTONE; RNA; UNTRANSLATED RNA;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; COLORECTAL CANCER; DIET; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FOLATE METABOLISM; GENE CONTROL; GENE MUTATION; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; LIFESTYLE; MATERNAL TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; REVIEW; UNTRANSLATED RNA DEREGULATION; VITAMIN SUPPLEMENTATION;

ANIMALS; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; PROGNOSIS;

EID: 84858276725     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2011.01829.x     Document Type: Review

References (63)

1. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 2010: 375: 1030-1047.
2. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011: 2011: 792362.
3. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999: 96: 8681-8686.
4. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008: 135: 1079-1099.
5. Esteller M. Epigenetic changes in cancer. Biology Reports 2011: 3: 9.
6. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007: 26: 5310-5318. Review.
7. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007: 1: 19-25.
8. Carmona FJ, Esteller M. Moving closer to a prognostic DNA methylation signature in colon cancer. Clin Cancer Res 2011: 17: 1215-1217.
9. Li Q, Chen H. Epigenetic modifications of metastasis suppressor genes in colon cancer metastasis. Epigenetics 2011: 6: 849-852.
10. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. PNAS 2007: 104: 47.
11. Wallace K, Grau MV, Levine AJ et al. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev Res 2010: 3: 1552-1564.
12. Azuara D, Rodriguez-Moranta F, de Oca J et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer 2010: 9: 168-176.
13. Hansen KD, Timp W, Bravo HC et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011: 43: 768-775.
14. Javierre BM, Rodriguez-Ubreva J, Al-Shahrour F et al. Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res 2011: 9: 1139-1151.
15. Ogoshi K, Hashimoto S, Nakatani Y et al. Genome-wide profiling of DNA methylation in human cancer cells. Genomics 2011: 98: 280-287.
16. Leong KJ, Wei W, Tannahill LA et al. Methylation profiling of rectal cancer identifies novel markers of early-stage disease. Br J Surg 2011: 98: 724-734.
17. Lara E, Calvanese V, Huidobro C et al. Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer 2010: 9: 170.
18. Zhang H, Widegren E, Wang DW, Sun HF. SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer. Tumor Biol 2011: 32: 1225-1231.
19. Lee BB, Lee EJ, Jung EH et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009: 15: 6185-6191.
20. Naghibalhossaini F, Hosseini HM, Mokarram P, Zamani M. High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. Pathol Oncol Res 2011: 17: 819-825.
21. Lind GE, Danielsen SA, Ahlquist T et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011: 10: 85.
22. Chen WD, Han ZJ, Skoletsky J et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005: 97: 1124-1132.
23. Devos T, Tetzner R, Model F et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009: 55: 1337-1346.
24. Grützmann R, Molnar B, Pilarsky C et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008: 3: e3759.
25. He Q, Chen HY, Bai EQ et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet 2010: 202: 1-10.
26. Isaksson-Mettävainio M, Palmqvist R, Dahlin AM, Van Guelpen B, Rutegård J, Oberg A. Henriksson MLHigh SMAD4 levels appear in MSI and hypermethylated colon cancers, and indicate a better prognosis. Int J Cancer. Epub 30 September 2011. DOI: 10.1002/ijc.26473.
27. Wang Z, Yuan X, Jiao N, Zhu H, Zhang Y, Tong J. CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathol Oncol Res. Epub 28 July 2011.
28. Yi JM, Dhir M, Van Neste L et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 2011: 17: 1535-1545.
29. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007: 128: 683-692.
30. Mossman D, Scott RJ. Long term transcriptional reactivation of epigenetically silence genes in colorectal cancer cell s requires DNA hypomethylation and histone acetlation. PLoS One 2011: 6: e23127.
31. Kim MS, Chung NG, Kang MR, Yoo NJ, Lee SH. Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology 2011: 58: 660-668.
32. Xiong H, Du W, Zhang YJ et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog 2012: 51: 174-184.
33. Ashktorab H, Belgrave K, Hosseinkhah F et al. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 2009: 54: 2109-2117.
34. Nakazawa T, Kondo T, Ma D et al. Global histone modification of histone H3 in colorectal cancer and its precursor lesion. Hum Pathol. Epub 13 September 2011.
35. Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor suppressor microRNAs in cancer. Oncogene. Epub 22 August 2011. DOI: 10.1038/onc.2011.354.
36. Liu M, Chen H. The role of microRNAs in colorectal cancer. J Genet Genomics 2010: 37: 347-358.
37. Song Y, Xu Y, Wang Z et al. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int J Cancer. Epub 23 October 2011. DOI: 10.1002/ijc.26485.
38. Tang JT, Wang JL, Du W et al. MicroRNA 345, a methylation sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 2011: 32: 1207-1215.
39. Kogo R, Shimamura T, Mimori K et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011: 71: 6320-6326.
40. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis 2011: 34: 101-109.
41. Kim YI. Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev 2008: 17: 2220-2225.
42. Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res 2007: 51: 267-292.
43. Lindzon GM, Medline A, Sohn KJ, Depeint F, Croxford R, Kim YI. Effect of folic acid supplementation on the progression of colorectal aberrant crypt foci. Carcinogenesis 2009: 30: 1536-1543.
44. Sie KK, Medline A, van Weel J et al. Effect of maternal and postweaning folic acid supplementation on colorectal cancer risk in the offspring. Gut 2011: 60: 1687-1694.
45. Cabelof DC, Raffoul JJ, Nakamura J, Kapoor D, Abdalla H, Heydari AR. Imbalanced base excision repair in response to folate deficiency is accelerated by polymerase haploinsufficiency. J Biol Chem 2004: 279: 36504-36513.
46. Mason JB, Dickstein A, Jacques PF et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomark Prev 2007: 16: 1325-1329.
47. Hirsch S, Sanchez H, Albala C et al. Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur J Gastroenterol Hepatol 2009: 21: 463-469.
48. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010: 59: 794-799.
49. Song J, Medline A, Mason JB, Gallinger S, Kim Y-I. Effects of dietary folate on intestinal tumorigenesis in the ApcMin Msh mouse. Cancer Res 2000: 60: 3191-3199.
50. de Vogel S, Wouters KA, Gottschalk RW et al. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009: 18: 3086-3096.
51. Levine AJ, Figueiredo JC, Lee W et al. A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2010: 19: 1812-1821.
52. Haghighi MM, Radpour R, Mahmoudi T, Mohebbi SR, Vahedi M. Zali MRAssociation between MTHFR polymorphism (C677T) with nonfamilial colorectal cancer. Oncol Res 2009: 18: 57-63.
53. Le Marchand L, Wilkens LR, Kolonel LN, Henderson BE. The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005: 14: 1198-1203.
54. Protiva P, Mason JB, Liu Z et al. Altered folate availability modifies the molecular environment of the human colorectum: implications for colorectal carcinogenesis. Cancer Prev Res (Phila) 2011: 4: 530-543.
55. Li M, Chen W, Papadopoulos N et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009: 27: 858-863.
56. Crea F, Nobili S, Paolicchi E et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat 2011: 14: 280-296.
57. Tikoo K, Ali IY, Gupta J, Gupta C. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Toxicol Lett 2009: 191: 158-166.
58. Venkataramani V, Rossner C, Iffland L et al. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem 2010: 285: 10678-10689.
59. Chou CW, Wu MS, Huang WC, Chen CC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 2011: 6: e18087.
60. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 2008: 105: 13421-13426.
61. Han HB, Gu J, Zuo HJ et al. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol. Epub 7 October 2011. DOI: 10.1002/path.3014.
62. Wang F, Zhang P, Ma Y et al. NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. Cancer Lett 2012: 314: 223-231.
63. Liu X, Zhang Z, Sun L et al. microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 2011: 32: 1798-1805.